EDGC And Diagnomics Sign As Initial Customer For Maverix Dx Platform
- Clinical Labs Will Launch Various NGS-based Clinical Diagnostic Products and Services on Clinically Validated Cloud-based Analysis and Reporting Systems -
SAN MATEO, CALIFORNIA – Maverix Biomics, Inc. today announced that EDGC (the Eone-Diagnomics Genome Center), a joint venture between an affiliate of the Eone Life Science Institute and Diagnomics, signed a contract to be the initial diagnostic testing customer on the Maverix Dx Platform. Eone is the largest clinical reference laboratory in Korea. The Maverix Dx Platform is a cloud-based solution designed for use by reference laboratories and diagnostic test developers. It leverages technologies developed and proven as part of the Maverix Analytic Platform, which includes open-source algorithms and supports proprietary algorithms developed to implement specific genomic-based tests and diagnostics. Detailed financial terms of the contract and projected test volumes have not been publicly released, but the parties confirm that the first year revenue value to Maverix will be in excess of $150,000.
Diagnomics and EDGC focus on the development of innovative products and services for personalized medicine based on Next Generation Sequencing (NGS) technology and cutting edge genomics analysis. The goal is to provide high-quality healthcare products and services to guide personalized medicine based on an individual’s genetic information. The organizations provide various personal genome sequencing and bioinformatics solutions to biomedical researchers, physicians and individuals seeking to understand the genetic influence of personal health and disease, including Non-Invasive Prenatal Testing (NIPT), and diagnostics for various cancers and rare genetic diseases.
EDGC is an international joint venture established in 2013 between the Eone Life Science Institute in Korea and Diagnomics, Inc. in San Diego, California. Eone Life Science provides 30 years of know-how and experience in clinical diagnostics and reference lab expertise in Korea, and Diagnomics contributes cutting edge genomics and next generation sequencing expertise. EDGC plans to revolutionize next generation healthcare based on personalized medicine. The EDGC joint venture is located in Songdo Inchon, Korea.
“We evaluated many options and chose the Maverix Dx Platform as the basis for delivering our NGS-based clinical diagnostic tests,” said Min Seob Lee PhD, CEO of EDGC and president of Diagnomics. “Our experience in working with Maverix on implementing and CLIA-validating our first test confirms their reputation for providing the highest quality, highest performance analytic platforms for NGS data.”
“Maverix is delighted to have been selected by EDGC and Diagnomics as the provider of their NGS-based clinical diagnostic test analysis and reporting,” said Byung-in Lee PhD, Vice President of Product Operations of Maverix. “We are excited to work with a leading clinical reference laboratory to launch new and more effective diagnostic solutions based on Next Generation Sequencing technology.”
About the Maverix Dx Platform
The Maverix Dx Platform is a cloud-based solution designed for use by reference laboratories and diagnostic test developers. It leverages technologies developed and proven as part of the Maverix Analytic Platform, including open-source algorithms as well as supporting proprietary algorithms developed to implement specific genomic-based tests and diagnostics. After loading sequence data from instruments located at one or more geographic locations, the diagnostic analysis is performed, and merged with additional information provided from external Laboratory Information Management Systems. PDF summary reports, including clinical reports, are generated and delivered through a web-based Provider Portal for viewing and downloading. The Maverix Dx Platform is designed to be part of a regulatory compliant workflow from sample to results.
About the Maverix Analytic Platform
The Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences researchers who may not have software or bioinformatics expertise. It leverages proven open-source algorithms and applications developed at leading academic and research centers. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analyses with reliable, scientifically vetted configurations, as cited in peer-reviewed journal publications. Visualization is provided through a variety of integrated graphical tools, including a private, secure version of the UCSC Genome Browser, the world’s most widely used genome browser.
About Maverix Biomics
Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms. Maverix also provides reference laboratories and diagnostic testing companies with a cloud-based platform for conducting analysis and generating reports as part of an NGS-based, regulatory compliant diagnostic testing workflow. For more information, visit www.maverixbio.com.
Help employers find you! Check out all the jobs and post your resume.
SAN MATEO, CALIFORNIA – Maverix Biomics, Inc. today announced that EDGC (the Eone-Diagnomics Genome Center), a joint venture between an affiliate of the Eone Life Science Institute and Diagnomics, signed a contract to be the initial diagnostic testing customer on the Maverix Dx Platform. Eone is the largest clinical reference laboratory in Korea. The Maverix Dx Platform is a cloud-based solution designed for use by reference laboratories and diagnostic test developers. It leverages technologies developed and proven as part of the Maverix Analytic Platform, which includes open-source algorithms and supports proprietary algorithms developed to implement specific genomic-based tests and diagnostics. Detailed financial terms of the contract and projected test volumes have not been publicly released, but the parties confirm that the first year revenue value to Maverix will be in excess of $150,000.
Diagnomics and EDGC focus on the development of innovative products and services for personalized medicine based on Next Generation Sequencing (NGS) technology and cutting edge genomics analysis. The goal is to provide high-quality healthcare products and services to guide personalized medicine based on an individual’s genetic information. The organizations provide various personal genome sequencing and bioinformatics solutions to biomedical researchers, physicians and individuals seeking to understand the genetic influence of personal health and disease, including Non-Invasive Prenatal Testing (NIPT), and diagnostics for various cancers and rare genetic diseases.
EDGC is an international joint venture established in 2013 between the Eone Life Science Institute in Korea and Diagnomics, Inc. in San Diego, California. Eone Life Science provides 30 years of know-how and experience in clinical diagnostics and reference lab expertise in Korea, and Diagnomics contributes cutting edge genomics and next generation sequencing expertise. EDGC plans to revolutionize next generation healthcare based on personalized medicine. The EDGC joint venture is located in Songdo Inchon, Korea.
“We evaluated many options and chose the Maverix Dx Platform as the basis for delivering our NGS-based clinical diagnostic tests,” said Min Seob Lee PhD, CEO of EDGC and president of Diagnomics. “Our experience in working with Maverix on implementing and CLIA-validating our first test confirms their reputation for providing the highest quality, highest performance analytic platforms for NGS data.”
“Maverix is delighted to have been selected by EDGC and Diagnomics as the provider of their NGS-based clinical diagnostic test analysis and reporting,” said Byung-in Lee PhD, Vice President of Product Operations of Maverix. “We are excited to work with a leading clinical reference laboratory to launch new and more effective diagnostic solutions based on Next Generation Sequencing technology.”
About the Maverix Dx Platform
The Maverix Dx Platform is a cloud-based solution designed for use by reference laboratories and diagnostic test developers. It leverages technologies developed and proven as part of the Maverix Analytic Platform, including open-source algorithms as well as supporting proprietary algorithms developed to implement specific genomic-based tests and diagnostics. After loading sequence data from instruments located at one or more geographic locations, the diagnostic analysis is performed, and merged with additional information provided from external Laboratory Information Management Systems. PDF summary reports, including clinical reports, are generated and delivered through a web-based Provider Portal for viewing and downloading. The Maverix Dx Platform is designed to be part of a regulatory compliant workflow from sample to results.
About the Maverix Analytic Platform
The Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences researchers who may not have software or bioinformatics expertise. It leverages proven open-source algorithms and applications developed at leading academic and research centers. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analyses with reliable, scientifically vetted configurations, as cited in peer-reviewed journal publications. Visualization is provided through a variety of integrated graphical tools, including a private, secure version of the UCSC Genome Browser, the world’s most widely used genome browser.
About Maverix Biomics
Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms. Maverix also provides reference laboratories and diagnostic testing companies with a cloud-based platform for conducting analysis and generating reports as part of an NGS-based, regulatory compliant diagnostic testing workflow. For more information, visit www.maverixbio.com.
Help employers find you! Check out all the jobs and post your resume.